Expansion potential Latham BioPharm Group is now part of Sia Partners’ life sciences division, signaling increased scale and cross-sell opportunities across pharma, biotech, CROs, academia, and medical devices. Use the combined platform to offer integrated product development, non-dilutive funding, and strategic consulting services to a broader set of clients.

Global health focus Recent news on developing a global health cost model platform and DARPA-funded live biotherapeutic product initiatives indicate growing demand for cost modeling, health economics, and innovative product development capabilities. Position these capabilities to health systems, government contractors, and biotech clients pursuing value-based strategies.

Funding and grants Non-dilutive funding is highlighted as a core service area. With the firm's depth in life sciences and government collaboration history, target early- to mid-stage biotech firms seeking grant support, SBIR/STTR opportunities, and strategic funding to de-risk product development and accelerate milestones.

Regulatory and development expertise Industry experience spanning pharma, biotech, CROs, academia, and medical devices positions the firm to advise on complex regulatory pathways and product development challenges. Target companies navigating IND/CTA submissions, quality/compliance transitions, or portfolio optimization.

Knowledgeable client base With a diverse client mix and a proven merger integration into Sia Partners’ life sciences practice, there is an opportunity to upsell through expanded services such as AI-enhanced consulting, governance models, and strategy alignment across multiple functions to drive long-term value.